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Background: Non-small cell lung cancer (NSCLC) accounts for 81% of all cases of lung cancer and they are often
fatal because 60% of the patients are diagnosed at an advanced stage. Besides the need for earlier diagnosis, there
is a high need for additional effective therapies. In this work, we investigated the feasibility of a lung cancer
progression mouse model, mimicking features of human aggressive NSCLC, as biological reservoir for potential
therapeutic targets and biomarkers.
Results: We performed RNA-seq profiling on total RNA extracted from lungs of a 30 week-old K-rasLA1/p53R172HΔg
and wild type (WT) mice to detect fusion genes and gene/exon-level differential expression associated to the
increase of tumor mass. Fusion events were not detected in K-rasLA1/p53R172HΔg tumors. Differential expression at
exon-level detected 33 genes with differential exon usage. Among them nine, i.e. those secreted or expressed on
the plasma membrane, were used for a meta-analysis of more than 500 NSCLC RNA-seq transcriptomes. None of
the genes showed a significant correlation between exon-level expression and disease prognosis. Differential
expression at gene-level allowed the identification of 1513 genes with a significant increase in expression
associated to tumor mass increase. 74 genes, i.e. those secreted or expressed on the plasma membrane, were used
for a meta-analysis of two transcriptomics datasets of human NSCLC samples, encompassing more than 900
samples. SPP1 was the only molecule whose over-expression resulted statistically related to poor outcome
regarding both survival and metastasis formation. Two other molecules showed over-expression associated to poor
outcome due to metastasis formation: GM-CSF and ADORA3. GM-CSF is a secreted protein, and we confirmed its
expression in the supernatant of a cell line derived by a K-rasLA1/p53R172HΔg mouse tumor. ADORA3 is instead
involved in the induction of p53-mediated apoptosis in lung cancer cell lines. Since in our model p53 is
inactivated, ADORA3 does not negatively affect tumor growth but remains expressed on tumor cells. Thus, it could
represent an interesting target for the development of antibody-targeted therapy on a subset of NSCLC, which are
p53 null and ADORA3 positive.
Conclusions: Our study provided a complete transcription overview of the K-rasLA1/p53R172HΔg mouse NSCLC
model. This approach allowed the detection of ADORA3 as a potential target for antibody-based therapy in p53
mutated tumors.
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Background
Lung cancer is the most common cause of neoplasia-
related death worldwide [1]. The vast majority of lung
cancer cases (approximately 80%) are non-small cell
lung cancers (NSCLC) and the remaining fraction is
small cell lung cancers. Only a minority of NSCLC
patients is suitable for radical treatment as curative care.
Approximately two thirds of patients are diagnosed at
an advanced stage, and of the remaining patients who
undergo curative surgery, 30-50% have a recurrence
with metastatic disease [2]. The 5-year relative survival
rate among patients diagnosed with NSCLC is only 15%.
Thus, the conventional treatments (i.e. surgery, radio-
therapy and chemotherapy), have apparently reached a
plateau of effectiveness in improving survival of
advanced NSCLC patients [3]. Thus, the treatment of
NSCLC is a major unmet need and new therapies focus-
ing on the molecular mechanisms of lung tumorigenesis
are urgently needed [4].
The discovery of new biomarkers for targeted thera-
pies could greatly change the management and prog-
nosis of many patients with NSCLC. Further, knowledge
of the molecular pathways and mutational drivers of
lung cancer will expand the use of targeted treatments.
Hopefully, the identification of new therapeutic targets
will provide personalized and precise treatments for
lung cancer patients in the near future.
Indeed, considerable efforts were made to discover
new molecular biomarkers associated to lung cancer,
which could be used as early diagnostic markers or as
new specific therapeutic targets to treat patients [5-7].
In our opinion, the identification of oncoantigens (i.e.
tumor associated antigens that have a causal role in the
promotion of tumor progression) [8,9] could provide
new and more promising targets for personalized treat-
ment in NSCLC.
In this study, we sought to identify new candidate bio-
markers and/or potential oncoantigens involved in both
initiation of lung cancer and/or its progression to an
aggressive cancer phenotype. To this aim, we adapted to
the lung cancer disease our consolidated pipeline for
oncoantigen detection [8,10]. Thanks to the RNA-seq
technology we also extended our pipeline to the detec-
tion of tumor specific transcript isoforms and fusion
proteins [11]. Our pipeline requires the availability of an
animal model for the cancer under study [8]. Thus, we
used one of the models most closely simulating human
metastatic lung cancer [12]. This model is based on the
combination of a latent mutant K-ras allele at the endo-
genous locus (K-rasLA1), which is spontaneously acti-
vated in vivo [13], and a particular mutation generated
at the endogenous p53 allele containing an arginine-to-
histidine substitution at codon 172 (p53R172HΔg), corre-
sponding to the hot spot mutation at human codon 175
[14-16]. This mouse model develops lung adenocarcino-
mas with a high incidence of metastases and gender dif-
ferences in cancer-related death. The use of our pipeline
in the framework of metastatic lung cancer model, com-
bined with the power of RNA-seq technology, allowed
the identification of ADORA3 as new putative target for
antibody-based therapy in mutant p53 tumors.
Results and discussion
Characterization of lung tumors of K-rasLA1/p53R172HΔg
mice by non invasive MRI
A colony of K-rasLA1/p53R172HΔg double transgenic mice
has been generated in our laboratory, by crossing one
p53R172HΔg male with one K-rasLA1 female, kindly pro-
vided us by Dr. Lozano (University of Texas, M.D.
Anderson Cancer Center). These mice develop auto-
chthonous lung adenocarcinomas with a high incidence
of metastases and gender differences in cancer related
death thus providing a realistic model of human meta-
static lung cancer and an immunocompetent system for
studying NSCLC and its prevention by novel agents
[12]. By using non-invasive imaging techniques (MRI)
for small rodents, a quantification of the number and
the size of tumor lesions of K-rasLA1/p53R172HΔg mice
during time was performed. The progression of lung
tumors was monitored at 10, 20 and 30 weeks of age.
Tumor lesions resulted as white opaque hyper-intense
regions already evident in 10 week-old K-rasLA1/p53
R172HΔg male and female mice (Figure 1A). The analysis
of images collected at weeks 10, 20, and 30 weeks of age
showed a significant increase in the total tumor volume
in both K-rasLA1/p53 R172HΔg males and females during
cancer progression (Figures 1B and 1C). Moreover,
starting from the 10th week of age, a significant increase
in the number and size of lung lesions was observed
between males and females, with females developing
more lesions than males, as previously reported for sur-
vival [12]. These gender differences remain evident from
early to advanced/late-stage of the disease (Figures 1B
and 1C).
Histological analysis of lung sections from normal
(Figure 2A) and 10 week-old K-rasLA1/p53R172HΔg male
and female mice showed that white opacities revealed by
the MRI analysis correspond to small foci of lung carci-
noma growing with lepidic aspect (Figure 2B). These
early lesions increase in number and dimensions and, at
20 weeks of age, become sub-pleural and intra-parenchy-
mal tumors (Figure 2C and 2D, respectively), growing in
masses with lepidic and solid growth aspects. Like in
humans, in which the prevalence of adenocarcinomas of
mixed subtypes led, in 2011, to a new WHO classification
in which invasive adenocarcinomas are classified by pre-
dominant pattern and to the routinely definition of the
percentage of histologic subtypes in clinical pathological
Riccardo et al. BMC Genomics 2014, 15(Suppl 3):S1
http://www.biomedcentral.com/1471-2164/15/S3/S1
Page 2 of 11
reports, at 30 weeks of age (Figure 2E,2F,2G,2H), lung
adenocarcinomas of K-rasLA1/p53R172HΔg mice display,
besides a predominance of zones with solid growth
(Figure 2E), several types of differentiation, sometimes
with prominent papillary growth pattern (Figure 2F),
sometimes with less differentiated zones and aspects of
large cell carcinoma (Figure 2G). Immunohistochemical
analyses showed that these lesions are positive for TTF-1
(Thyroid Transcription Factor-1; Figure 2H), a typical
marker of adenocarcinoma [17], and negative for p63, a
marker of squamous tumors and for Synaptophysin,
Chromogranin, and Neuron Specific Enolase (NSE; data
not shown), markers of neuroendocrine tumors [18].
Transcription profiling
Microarray analysis
To estimate the importance of the gender effect on gene
expression, we initially run a microarray experiment on
lung tissues of 10, 20 and 30 week-old K-rasLA1/
p53R172HΔg mice, using Affymetrix exon 1.0 arrays. The
comparison did not show any significant difference at
the transcription level (not shown), suggesting that the
differences in growth rate might be due to the endocri-
nological differences existing between male and female.
Thus, we run a pair-end RNA-seq on two prototypical
situations, WT and K-rasLA1/p53R172HΔg mice (MT), to
detect genes/transcripts associated to the increase of
tumor mass that might represent potential targets for
precision medicine applications [19].
Fusion events detection
Direct sequencing of messenger RNA transcripts using
the RNA-seq protocol [20] is rapidly becoming the stan-
dard method for detecting and quantifying expressed
genes in a cell. One of the key features observed after
cancer genomes analysis is a chromosomal abnormality.
Genome rearrangements could result in aberrant gene
fusions, and a number of them have been found to play
important roles in carcinogenesis [21]. The discovery of
novel gene fusions can lead to a better comprehension of
cancer progression and development. Fusion events were
detected in WT and MT samples using ChimeraScan
Figure 1 Non-invasive imaging techniques (MRI) for small rodents. A: T2 weighted images of the lungs from 10, 20 and 30 weeks old
K-rasLA1/p53R172HΔ males (left panels) and females (right panels) mice. Tumors appear as white opaque hyper-intense regions (white arrows).
B and C: Quantification of the tumor burden of both males (black bars) and females (white bars) mice at 10, 20 and 30 weeks of age. B: Tumor
volume per animal was quantified by calculating the area of visible lung opacities present in each axial image sequence (usually 18-20 per
mouse) and then multiplying the total sum of the areas by the distance between each MRI sequence. Data are shown as mean ± SEM of the
areas occupied by the tumors in the lung of each mouse (** p = 0.005, *** p = 0.0001, Student’ t test). C: Percentage of lung volume occupied
by tumors; data are shown as mean ± SEM of each mouse (** p = 0.005, Student’ t test).
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[22]. Since fusion detection tools are error prone [23], we
filtered the putative fusions, reported by ChimeraScan,
retaining only common events between the MT and not
reported in the WT replicates. The detected fusions
(AK029407:Ank3, Gimap1:Gimap5, Pisd-ps2:Pisd-ps)
were subsequently discarded since they were all either
read through events or fusions between homologue
genes. Thus it seems that fusion products are not promi-
nent events in tumors developing due to the presence of
constitutively active K-ras and inactive p53.
Exon-level analysis
Exon level analysis was run using DEXSeq Bioconduc-
tor package [24] and provided 33 genes with differen-
tial exon expression between WT and MT groups
(FDR < 10%). Among them six (ITGAD, COL17A1,
DCSTAMP, PTPRN, PTPRM and Klrb1c) codify for
proteins that were located on the plasma membrane
and three (VWF, DMKN and TIMP3) for proteins
secreted in the extracellular space. For 11 of the 33
detected genes, exon-level data for 509 tumors together
with their clinical annotation were retrieved from the
cancer genome atlas (http://cancergenome.nih.gov/).
We scored the exons for their oncological power (see
methods), which essentially represents the association
between exon skipping/retention and poor outcome.
Significant correlation between exon-level expression
for the above-mentioned genes and poor prognosis
could not be detected (not shown).
Gene-level analysis
Gene-level analysis was run using DESeq Bioconductor
package [25] and provided 1,513 genes with increased
expression associated to tumor mass increment between
WT and MT groups (FDR < 10%, |log2FC| > 1). We
focused our analysis on 74 genes encoding for secreted
and membrane bound proteins having a human ortholog
(74). Thus, we run a meta-analysis on a set of public
available transcriptomes of 989 NSCLC patients charac-
terized by clinical outcome for survival and metastasis
(see methods). The data set was divided in test and vali-
dation set, of 695 and 294 samples each, respectively. We
scored the identified genes for their oncological power
(CO score, see methods), which represents the associa-
tion between up-modulation of a gene and poor clinical
outcome.
SPP1 (osteopontin) was the only molecule whose over-
expression resulted statistically related to poor outcome
regarding both survival and metastasis formation in
NSCLC patients examined (Figure 3). This result was
further maintained in both datasets evaluating only early
tumor stage samples, i.e. category T1 based on the TNM
staging system [26]. These results are in accordance with
previous evidences that SPP1 is an early marker of tumor
progression in NSCLC [27,28]. Among the identified
genes, two additional molecules showed a significant
over-expression in patients with poor outcome regarding
metastasis formation: GM-CSF (Figure 4) and ADORA3
(Figure 5).
Figure 2 Morphological characterization of lung tumors from K-rasLA1/p53R172HΔg mice. A-G: Hematoxylin-eosin evaluation of lung sections
from a WT transgenic mouse (A), one representative 10- (B), 20- (C) and 30- (D-G) week-old K-rasLA1/p53R172HΔg mice (A-D magnification ×200;
E-G magnification ×400). A: normal lung tissue; B: initial lesions with aspects of lepidic growth; C: subpleural lesion with papillary and solid
patterns; D: adenocarcinoma nodule with solid pattern of growth; E: tumor zone with a solid growth pattern composed of cohesive cell
agglomerates in a nest-like configuration without acinar polarity; F: tumor zone with papillary growth. Papillae show fibrovascular cores lined by
cells with large vesicular nuclei containing very prominent nucleoli; G: poorly differentiated tumor zone with highly polymorphic cells and cells
with aberrant nuclei. H: Immunohistochemical staining for TTF-1 lung tumor lesions from one representative 30-week-old K-rasLA1/p53R172HΔg
mouse (magnification ×100).
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GM-CSF, the granulocyte and macrophage colony sti-
mulating factor, is a monomeric, 4-helical, secreted cyto-
kine known to inhibit inflammation and T-cell
immunity [29]. It has been described to promote cancer
in pancreatic ductal neoplasia when over-expressed by a
constitutively active form of K-ras [30], in accordance
with our previously observed results in K-rasLA1/
p53R172HΔg mice. The association of GM-CSF expression
Figure 3 SPP1 clinical outcome evaluation. SPP1 showed a significant (p < 0.05) poor outcome in case of over-expression for both survival, in
test (A) and validation data sets (C), and metastasis formation, in test (B) and validation data sets (D).
Figure 4 GM-CSF clinical outcome evaluation. GM-CSF showed a significant (p < 0.05) poor outcome regarding metastasis formation in case
of over-expression in the test dataset (A). The significance was lost in the validation dataset (B), probably because of lack of sufficient data.
Significance in test dataset was maintained when considering only early stage tumors (C).
Riccardo et al. BMC Genomics 2014, 15(Suppl 3):S1
http://www.biomedcentral.com/1471-2164/15/S3/S1
Page 5 of 11
with poor outcome was obtained in the test dataset. The
result could not be confirmed in the validation dataset
probably due to the limited number of samples in high
expression cluster (Figure 4B, red curve). Nevertheless,
significance in the first dataset was maintained even
only considering early stage T1 tumors (Figure 4C).
Analysis of the supernatants from a cell line (KP cells)
derived from a lung tumor of a 30 week-old K-rasLA1/
p53R172HΔg mouse confirmed that they express GM-CSF
(Figure 6). Taken together our data, with the observa-
tion that serum level of GM-CSF is significantly higher
in colon adenocarcinoma patients [31], suggest that
GM-CSF might represent a putative early marker in
lung adenocarcinoma detection.
ADORA3 is a member of a family of 7-transmem-
brane G-protein-coupled receptor for adenosine. It has
been reported to be involved in cell cycle regulation and
tumor growth control both in vitro and in vivo [32]. It
has been recently shown [33] that ADORA3 is involved
in the induction of p53-mediated apoptosis in lung can-
cer cell lines. Since in our model p53 is inactivated,
ADORA3 does not negatively affect tumor growth, but
remain expressed on tumor cells. Although it does not
represent a suitable oncoantigen, since its expression
does not strictly affect tumor behavior; however, since it
is a tumor associated antigen it could represent an inter-
esting target for the development of antibody-mediated
therapy on the subset of NSCLC which are p53 null and
ADORA3 positive.
Figure 5 ADORA3 clinical outcome evaluation. ADORA3 showed a significant (p = 0.05) poor outcome regarding metastasis formation in case of
over-expression in both test (A) and validation (B) datasets we considered. Its role is connected to late stages of cancer development (> 2 years).
Figure 6 GM-CSF production by KP cells. The presence of GM-
CSF was tested in the supernatant of KP cells after 24, 48, 72 and
96 hours of culture by ELISA. Results are expressed as the mean of
three different supernatants ± SEM. The experiment was performed
three times and a representative one is here shown.
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Conclusions
The combination of powerful transcriptomics analysis,
i.e. RNA-seq, genetically engineered mice models prone
to develop tumors and large collection of human tumor
transcriptomes offers new opportunities for the discovery
and validation of therapeutic targets in the framework of
personalized medicine. The identification of a known
biomarker as osteopontin in the NSCLC mouse model
confirmed the efficacy of our pipeline to detect targets in
precision medicine. Moreover, our approach also allowed
the identification of a new putative target, ADORA3, as
well as a new putative biomarker, GM-CSF.
Methods
Mice
The heterozygous K-rasLA1 mice were crossed with het-
erozygous p53R172HΔg mice (both kindly provided by
Dr. G. Lozano, University of Texas, Houston, TX, USA)
to generate K-rasLA1/p53R172HΔg and WT mice. The
background of these mice was 129/Sv. Mice were main-
tained in the transgenic unit of the Molecular Biotech-
nology Center (University of Torino) under a 12 hour
light-dark cycle and provided food and water ad libitum.
Genotyped and individually tagged mice of the same age
were treated in conformity with national and interna-
tional laws and policies as approved by the Faculty
Ethical Committee and all animal experiments were per-
formed in accordance with European Union guidelines
and national institutional regulations. Genotyping of
K-rasLA1 mice was performed as previously described
[13]. To determine p53R172HΔg mouse genotypes, PCR
analysis was performed on tail DNA using the following
primer sets: BMGFD (covering part of intron 4 and of
the exon 5; 5’- TCT CTT CCA GTA CTC TCC TC -3’)
and BMGRV (covering the end of exon 7 and part of
intron 7; 5’- GCC TTC CTA CCT GGA GTC TT -3’)
(Invitrogen Corp., Carlsbad, CA) for the amplification of
p53 allele. The resulting PCR product was then digested
with HgaI restriction enzyme (Invitrogen) to discrimi-
nate p53 WT from p53R172HΔg mutant alleles.
Cell line
KP is a cloned cell line established in vitro from a lung
carcinoma that arose spontaneously in a K-rasLA1/
p53R172HΔg mouse. KP cells were cultured in DMEM
with Glutamax 1 (DMEM, Life Technologies) supple-
mented with 20% heat-inactivated fetal bovine serum
(Invitrogen).
Magnetic Resonance Imaging (MRI)
MR images were acquired on a Bruker Avance 300 (Bru-
ker, Ettlingen, Germany) operating at 7T using a 30 mm
insert birdcage. Mice at different weeks of age (i.e. 10,
20 and 30 weeks, n = 3 each group) were anesthetized by
injecting intramuscularly a mixture of tiletamine/zolaze-
pam 20 mg/kg (Zoletil 100; Virbac, Milperra, Australia)
and 5 mg/kg xylazine (Rompun; Bayer, Milano, Italy).
Breath rate was monitored throughout in vivo MRI
experiments using a respiratory air pillow (SA Instru-
ments, Stony Brook, NY).
T2w axial, coronal and sagittal MR images with an
in-plane resolution of 100 μm were acquired with a breath-
triggered sequence respiratory gating to reduce lung move-
ment artefacts using a RARE sequence (typical setting TR/
TE/NEX/RARE factor = 6.0 s/4.14 ms/2/16) preceded by a
fat-suppression module. A 256 × 256 acquisition matrix
was used with a field of view of 25 × 25 mm2. The slice
thickness was 1 mm, and the number of slices was 18 to 20,
which was sufficient to cover the entire lung so that tumor
volume could be measured. The T2w sequence can display
the tumor location, size, and shape in both left and right
lungs, providing clear boundaries with normal lung tissue.
Tumor Volume Measurements
Data analysis of MR images was performed by using an
open source application, ITK-Snap (http://www.itksnap.
org), for segmentation of the lung nodules in three-
dimensions, calculating both the number and the size of
tumor lesions [34]. Tumor volume per animal was quan-
tified by calculating the area of visible lung opacities
hyper intense regions present in each axial or coronal
image slice sequence (usually 18-20 per mouse) and then
multiplying the sum of the areas by the distance between
each MRI sequence slice. The post-processing of the seg-
mented data provides the voxel counts and the volume
(mm3) and displays the shape of the segmented structure.
Tumor volumes were normalized relative to the total
lung volumes at the indicated times and expressed as
percentage of lung volume occupied by tumors.
Lung tumor collection
Normal lung tissues and primary lung adenocarcinomas
were collected from WT and K-rasLA1/p53R172HΔg mice, at
different stages of cancer progression (corresponding to
10, 20 and 30 weeks of age). Groups of three to six WT
and K-rasLA1/p53R172HΔg mice were sacrificed by cervical
dislocation at the indicated times. Specimens for RNA
extraction and gene expression profile analysis were stored
in RNA later (Sigma-Aldrich, Milano, Italy) at 4° C for
24 h and then snap-frozen in liquid nitrogen and stored at
-80° C until use. Tissues for histological and immunohisto-
chemical studies were fixed in 10% neutral-buffered
formalin and embedded in paraffin.
Histopathological and immunohistochemical analysis
Tumors and tissues collected from K-rasLA1/p53R172HΔg
mice were fixed in formalin or PLP (Paraformaldehyde/
Lysine/Periodate) and embedded in paraffin or frozen in
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OCT, respectively. Sections were stained with hematoxylin
and eosin (H&E) for histological evaluation. Immunohisto-
chemical staining was performed with the following pri-
mary antibodies: anti-TTF-1 (Thyroid Transcription
Factor-1), anti-p63, anti-Synaptophysin and anti-Neuron
Specific Enolase (NSE). Slides were then incubated with
the appropriate biotinylated secondary antibody. Immu-
noreactive antigens were detected using NeutrAvidin™
Alkaline Phosphatase Conjugated (Thermo Scientific-
Pierce Biotechnology, Rockford, USA) and Vulcan Fast
Red (Biocare Medical, Concord, CA) or DAB Chromogen
System (Dako Corporation, Carpinteria, CA, USA).
RNA extraction
Total RNA was isolated from lung specimens by using
an IKA-Ultra-Turrax® T8 homogenizer (IKA-Werke,
Staufen, Germany) and TRIzol® reagent (Invitrogen),
according to the manufacturer’s instructions. Genomic
DNA contaminations were removed from total RNA by
using DNA-free kit (Ambion, Warrington, England) as
per manufacturer’s instructions. Total RNA concentra-
tion and purity were assessed using NanoVue Plus Spec-
trophotometer (GE Healthcare, Milano, Italy); RNA
quality was evaluated on an Agilent 2100 Bioanalyzer
following the manufacture’s recommendations (Agilent
Technologies, Milano, Italy), with a RNA integrity num-
ber (RIN) greater than 8.0 considered acceptable for
expression profiling by microarray.
Microarray data generation and analysis
Total RNA was then used to create the biotin-labelled
cDNA probes to be hybridized on GeneChips Exon 1.0
ST mouse microarrays following the procedure
described by the manufacturer (Affymetrix, Santa Clara,
CA). Arrays were scanned on Affymetrix Gene ChIP
Scanner 3000 7G and the CEL files were analysed as
follows.
The CEL files resulting from the analysis of image files
were analysed using oneChannelGUI 1.6.5 [35]. Gene-
level expression was calculated using RMA method
(Robust Multichip Average) [36] and normalized by
quantile sketch method [37].
The gender effect was modelled to evaluate if any
gene was associated to the difference in tumor growth
observed between males and females.
The maSigPro Bioconductor library was used to assess
differential expression at gene level [38]. maSigPro statis-
tics follows a two-step regression strategy. It first adjusts
the model by the least squared technique to identify dif-
ferentially expressed genes and selects significant genes
applying false discovery rate control procedures (FDR ≤
0.05). Secondly, backward stepwise regression is applied
to study differences between experimental groups (p ≤
0.05). The final list of significant differentially expressed
genes is defined using the R2 values (R2 ≥ 0.6) of this sec-
ond step.
Data were deposited on GEO database: GSE30878
RNA-seq and transcriptome analysis
RNA libraries were sequenced using (HiSeq2000, Illu-
mina, CA, USA). Two pools of total RNA extracted
from 30 week-old mice (n = 3) were generated for WT
and MT. Each pool was sequences twice to increase the
coverage. A total of 51,756,477 and 70,406,984 paired-
end (PE) reads were obtained for the first and the sec-
ond MT replicates, respectively. In the case of the WT
replicates 79,079,459 and 63,675,355 PE reads were
observed, respectively. Data were deposited on GEO
database: GSE51144
Fusion detection
De-novo discovery of chimeric transcripts was done by
ChimeraScan [22] with default parameters. For the first
and the second MT datasets 5066 and 4543 putative
events were measured, respectively. 4533 and 4351 puta-
tive events were found for the first and second WT
dataset, respectively. Gene fusions were annotated using
chimera Bioconductor package. Only the fusion events
in common between replicates were retained.
Gene/Exon-level analysis
Reads were mapped on mouse reference genome mm9
using TopHat version 2.0.4, using default parameters
and UCSC annotation (http://genome.ucsc.edu/).
Mapped reads were counted for each replicate of WT
and MT using DEXSeq package [24]. Briefly, dexseq_-
count.py script was used to associate reads to exons and
differentially expressed exons were detected using FDR
< 0.1 and |log2Fold Change| > 1.
Then, geneCountTable function was used to collapse
exon-level in gene-level counts. Differential expression
was subsequently evaluated using DESeq package [25]
(FDR < 0.1, |log2Fold Change| > 1).
Collection and processing of lung cancer expression data
Microarrays
Seven datasets containing microarray data of lung can-
cer samples (adenocarcinoma and squamous cell carci-
noma) and annotations on patients’ clinical outcome
were collected. All data were measured on different
Affymetrix arrays and have been downloaded from
NCBI Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/), caArray (https://array.nci.nih.
gov/caarray/home.action), and the Computational Biol-
ogy Center of the Memorial Sloan-Kettering Cancer
Center (http://cbio.mskcc.org/). The complete list of
datasets is provided in Table 1.
Prior to analysis, the datasets were reorganized by
eliminating duplicate samples and samples without out-
come information. Briefly, the original studies have been
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modified as follows: GSE3141 [39] has been re-named as
Duke (Duke University) and used as it is; GSE19188 [40]
has been re-named EMC and used after removal of sam-
ples lacking the patient outcome information; Shedden
[41] has been split into MI (187 samples from the Uni-
versity of Michigan Cancer Center), DFCI (82 samples
of the Dana-Farber Cancer Institute); HLM (92 samples
collected at the Moffitt Cancer Center), and MSKCC_1
(107 samples from the Memorial Sloan-Kettering Cancer
Center); Ladanyi-Gerald [42,43] has been re-named as
MSKCC_2 (Memorial Sloan-Kettering Cancer Center)
and used as it is; GSE10245 [44] has been re-named
DKFZ (German Cancer Research Center) and used as it
is; GSE31210 [45] re-named NCCRI (National Cancer
Center Research Institute, Japan) and used as it is;
GSE14814 [45] re-named OCI-PMH (Ontario Cancer
Institute, Princess Margaret Hospital) and used after
removal of large cell undifferentiated carcinoma sam-
ples. This re-organization resulted in a compendium
(meta-dataset) comprising 989 unique adenocarcinoma
samples from seven independent cohorts. The type and
content of clinical and pathological annotations of the
meta-dataset samples have been derived from the origi-
nal cohorts.
According to Cordenonsi et al., [46] clinical informa-
tion among the various datasets was standardized rede-
fining the outcome descriptions based on the clinical
annotations of each individual study. Specifically, we
defined two major types of events, i.e., metastasis and
survival.
Raw expression data (i.e., CEL files) obtained from dif-
ferent platforms was integrated using an approach
inspired by geometry and probe content of HG-U133
Affymetrix arrays [47]. Briefly, probes with the same oli-
gonucleotide sequence, but located at different coordi-
nates on different type of arrays, have been arranged in
a virtual platform grid. As for any other microarray geo-
metry, this virtual grid has been used as a reference to
create a virtual Chip Definition File (virtual-CDF), con-
taining probes shared among the various HG-U133 plat-
forms and their coordinates on the virtual platform, and
a virtual-CEL file containing the fluorescence intensities
of the original CEL files properly re-mapped on the
virtual grid. Expression values for 21981 meta-probesets
were generated from the transformed virtual-CEL files
using a virtual-CDF obtained merging HG-U133A, HG-
U133Av2, and HG-U133 Plus2 original CDFs. Fluores-
cence signals were background adjusted, normalized
using quantile normalization, and gene expression levels
calculated using median polish summarization (RMA;
[48]). The entire procedure was implemented as an R
script. The meta-dataset is available upon request to the
authors.
RNAseq
Public RNA sequencing human lung adenocarcinoma
data and related clinical metadata were downloaded
from The Cancer Genome Atlas repositories (http://can-
cergenome.nih.gov/). Two datasets were available at the
day of the download, containing respectively a total of
162 (RNASeq) and 452 (RNASeqV2) samples with
exon-level expressions. After filtering the transcriptomes
on the basis of the available clinical annotations we
obtained a dataset of 509 NSCLC adenocarcinoma tran-
scriptomes (Additional file 1). The entire procedure was
implemented as an R script.
Clinical Outcome score evaluation
The microarray meta-dataset was split in two separate
groups containing respectively 695 (from cohorts pub-
lished between 2005 and 2009) and 294 samples (from
cohorts published between 2011 and 2012).
Exon-level analysis was done on 137 and 372 samples
derived from Cancer Genome Atlas RNASeq dataset
and from RNASeqV2 dataset, respectively
Expression levels of each putative target (gene/exon)
discovered by the analysis of RNA-seq data were divided
in two clusters using a k-means clustering (k = 2). Med-
ian expression for each cluster was calculated. The label
“UP” was associated to the cluster characterized by the
higher median expression, while the other cluster was
labelled “DOWN”.
Exponential survival models [49] from the survival R
package, were fitted for the UP and DOWN clusters and
the significance (Ptrue) of the differences between the
models were tested [50]. Then, we performed a random
assignment of UP and DOWN labels to the samples and
Table 1 Original lung cancer datasets
Source Affymetrix platform Samples References
GEO GSE3141 HG-U133 Plus 2.0 111 Bild et al., 2006 [51]
GEO GSE19188 HG-U133 Plus 2.0 156 Hou J et al., 2010 [40]
caArray jacob-00182 HG-U133A 468 Shedden et al., 2008 [52]
http://cbio.mskcc.org/Public/lung_array_data/ HG-U133Av2 129 Nguyen et al., 2009 [42]; Chitale et al., 2009 [43]
GEO GSE10245 HG-U133 Plus 2.0 58 Kuner et al., 2009 [44]
GEO GSE31210 HG-U133 Plus 2.0 226 Okayama H et al., 2012 [45,53]
GEO GSE14814 HG-U133A 90 Zhu CQ et al., 2010 [54]
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we tested the significance (P*) of the difference between
these null models. This procedure was repeated n times
(n = 10000), randomly removing, at each repetition step,
10% of the samples.
Clinical Outcome score (CO) was then calculated with
the following formula:
CO = on
FR and EQ generated the animal model and prepared
samples for histological and microarray analysis, MA
and AF prepared samples for RNA-seq, GB and EZ
sequenced the RNA-seq libraries, MI did the histological
analyses, DLL run the NMR analyses. MC and RAC did
transcriptome data analysis; SN and SB prepared the
lung transcriptome dataset. PN and LL generate the KP
cell line. RAC, FC and EQ conceived, designed and
supervised the study, and wrote the paper.
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